Aim: Brain metastases, seen in ∼30-50% of NSCLC pts, are associated with poor prognosis. ALK+ NSCLC is sensitive to the ALK inhibitor (ALKi) crizotinib, but resistance invariably occurs, often with progression in new or existing brain metastases. Ceritinib (LDK378), a novel ALKi, is highly active in pts with ALK+ NSCLC and has demonstrated central nervous system activity. Here we report efficacy and safety of ceritinib therapy in the subset of ALK+ NSCLC pts with brain metastases treated in the phase I ASCEND-1 study. Methods: Safety and efficacy of ceritinib 750 mg/day was analyzed based on investigator assessment of adult pts with advanced ALK+ NSCLC and with clinically and neurologically stable brain metastases at study entry. Results: Of 246 ALK+ NSCLC pts at 750 mg/day, 124 had brain metastases at study entry; 98 had ALKi pretreatment and 26 were ALKi treatment naïve. Pts with brain metastases had a median age of 51.0 years; 85.5% had an ECOG performance status of ≤1. Most pts were either Caucasian (58.1%) or Asian (39.5%); median time from initial NSCLC diagnosis to first ceritinib dose was 20.5 months. Median duration of exposure to ceritinib was 27 weeks. Efficacy is shown below. Brain metastases were identified by investigator assessment as target lesions in 14 pts at baseline using RECIST 1.0 criteria (10 ALKi pretreated, 4 ALKi naïve). Of these, 7 achieved complete or partial responses in the brain (4 ALKi pretreated; 3 ALKi naïve) while 3 had stable disease (all ALKi pretreated). Most common adverse events (all grades; grade 3) in the 124 pts with brain metastases were nausea (82.3%; 4.0%), diarrhea (79.0%; 4.8%), and vomiting (62.9%; 6.5%); no grade 4 observations for these adverse events.
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Conclusions: Ceritinib 750 mg/day was efficacious in pts with brain metastases, whether ALKi pretreated or ALKi naïve.
